Compare Ferrari NV (RACE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs TG Therapeutics Inc — how do they compare? Ferrari NV trades at $403.79 (market cap $71.13B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Ferrari NV is far larger — about 8.3× TG Therapeutics Inc's market cap, and Ferrari NV pays a 1.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RACE | TGTX | |
|---|---|---|
Market Cap | $71.13B | $8.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $504.09 | $59.06 |
52-Week Low | $314.63 | $26.94 |
Enterprise Value | $73.08B | $8.74B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $405.94, down 0.98% on the day, with technical indicators showing a bearish trend while fundamentals remain strong. The company reported solid Q2 2026 earnings of $2.99 EPS, beating estimates, and maintains robust profitability with 22.25% net margins. Recent news highlights Ferrari's first electric vehicle selling for $40 million at auction, demonstrating brand strength. Analyst consensus remains bullish with a $462.67 price target representing 14% upside potential from current levels.
Ferrari presents a compelling growth story with premium valuation justified by strong fundamentals, though elevated multiples leave little room for execution missteps. Key risks include luxury market cyclicality and electric vehicle transition challenges, while institutional buying activity supports long-term confidence. The stock's current technical weakness may present entry opportunities for investors believing in the company's brand power and margin stability.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
